Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Adjunctive host-directed therapy with statins improves tuberculosis-related outcomes in mice.

Dutta NK, Bruiners N, Zimmerman MD, Tan S, Dartois V, Gennaro ML, Karakousis PC.

J Infect Dis. 2019 Oct 12. pii: jiz517. doi: 10.1093/infdis/jiz517. [Epub ahead of print]

PMID:
31605489
2.

Inhibiting the stringent response blocks Mycobacterium tuberculosis entry into quiescence and reduces persistence.

Dutta NK, Klinkenberg LG, Vazquez MJ, Segura-Carro D, Colmenarejo G, Ramon F, Rodriguez-Miquel B, Mata-Cantero L, Porras-De Francisco E, Chuang YM, Rubin H, Lee JJ, Eoh H, Bader JS, Perez-Herran E, Mendoza-Losana A, Karakousis PC.

Sci Adv. 2019 Mar 20;5(3):eaav2104. doi: 10.1126/sciadv.aav2104. eCollection 2019 Mar.

3.

Remembering the Host in Tuberculosis Drug Development.

Frank DJ, Horne DJ, Dutta NK, Shaku MT, Madensein R, Hawn TR, Steyn AJC, Karakousis PC, Kana BD, Meintjes G, Laughon B, Tanvir Z.

J Infect Dis. 2019 Apr 19;219(10):1518-1524. doi: 10.1093/infdis/jiy712.

PMID:
30590592
4.

Transcriptional Approach for Decoding the Mechanism of rpoC Compensatory Mutations for the Fitness Cost in Rifampicin-Resistant Mycobacterium tuberculosis.

Xu Z, Zhou A, Wu J, Zhou A, Li J, Zhang S, Wu W, Karakousis PC, Yao YF.

Front Microbiol. 2018 Nov 30;9:2895. doi: 10.3389/fmicb.2018.02895. eCollection 2018.

5.

Genome analysis of Mycobacterium avium subspecies hominissuis strain 109.

Matern WM, Bader JS, Karakousis PC.

Sci Data. 2018 Dec 4;5:180277. doi: 10.1038/sdata.2018.277.

6.

Unprecedented in Vitro Antitubercular Activitiy of Manganese(II) Complexes Containing 1,10-Phenanthroline and Dicarboxylate Ligands: Increased Activity, Superior Selectivity, and Lower Toxicity in Comparison to Their Copper(II) Analogs.

McCarron P, McCann M, Devereux M, Kavanagh K, Skerry C, Karakousis PC, Aor AC, Mello TP, Santos ALS, Campos DL, Pavan FR.

Front Microbiol. 2018 Jul 2;9:1432. doi: 10.3389/fmicb.2018.01432. eCollection 2018.

7.

Gene Enrichment Analysis Reveals Major Regulators of Mycobacterium tuberculosis Gene Expression in Two Models of Antibiotic Tolerance.

Matern WM, Rifat D, Bader JS, Karakousis PC.

Front Microbiol. 2018 Apr 4;9:610. doi: 10.3389/fmicb.2018.00610. eCollection 2018.

8.

Altered Mycobacterium tuberculosis Cell Wall Metabolism and Physiology Associated With RpoB Mutation H526D.

Campodónico VL, Rifat D, Chuang YM, Ioerger TR, Karakousis PC.

Front Microbiol. 2018 Mar 19;9:494. doi: 10.3389/fmicb.2018.00494. eCollection 2018.

9.

Intranasal Immunization with DnaK Protein Induces Protective Mucosal Immunity against Tuberculosis in CD4-Depleted Mice.

Chuang YM, Pinn ML, Karakousis PC, Hung CF.

Front Cell Infect Microbiol. 2018 Feb 8;8:31. doi: 10.3389/fcimb.2018.00031. eCollection 2018.

10.

Erratum for Dutta et al., "Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice".

Dutta NK, Pinn ML, Karakousis PC.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02493-17. doi: 10.1128/AAC.02493-17. Print 2018 Feb. No abstract available.

11.

Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment.

Degner NR, Wang JY, Golub JE, Karakousis PC.

Clin Infect Dis. 2018 Jan 6;66(2):198-205. doi: 10.1093/cid/cix819.

12.

Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13.

Aggarwal A, Parai MK, Shetty N, Wallis D, Woolhiser L, Hastings C, Dutta NK, Galaviz S, Dhakal RC, Shrestha R, Wakabayashi S, Walpole C, Matthews D, Floyd D, Scullion P, Riley J, Epemolu O, Norval S, Snavely T, Robertson GT, Rubin EJ, Ioerger TR, Sirgel FA, van der Merwe R, van Helden PD, Keller P, Böttger EC, Karakousis PC, Lenaerts AJ, Sacchettini JC.

Cell. 2017 Jul 13;170(2):249-259.e25. doi: 10.1016/j.cell.2017.06.025. Epub 2017 Jun 29.

13.

Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice.

Dutta NK, Pinn ML, Karakousis PC.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00652-17. doi: 10.1128/AAC.00652-17. Print 2017 Aug. Erratum in: Antimicrob Agents Chemother. 2018 Jan 25;62(2):.

14.

In vitro and in vivo fitness costs associated with Mycobacterium tuberculosis RpoB mutation H526D.

Rifat D, Campodónico VL, Tao J, Miller JA, Alp A, Yao Y, Karakousis PC.

Future Microbiol. 2017 Jul;12:753-765. doi: 10.2217/fmb-2017-0022. Epub 2017 Mar 27.

15.

Empirical Antifungal Therapy in Critically Ill Patients With Sepsis: Another Case of Less Is More in the ICU.

Siddharthan T, Karakousis PC, Checkley W.

JAMA. 2016 Oct 18;316(15):1549-1550. doi: 10.1001/jama.2016.13801. No abstract available.

PMID:
27706463
16.

Stringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo.

Chuang YM, Dutta NK, Hung CF, Wu TC, Rubin H, Karakousis PC.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6460-6470. doi: 10.1128/AAC.01139-16. Print 2016 Nov.

17.

Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen.

Dutta NK, He R, Pinn ML, He Y, Burrows F, Zhang ZY, Karakousis PC.

ACS Infect Dis. 2016 Mar 11;2(3):231-239. Epub 2015 Dec 24.

18.

First Evaluation of GenoType MTBDRplus 2.0 Performed Directly on Respiratory Specimens in Central America.

Lanzas F, Ioerger TR, Shah H, Acosta W, Karakousis PC.

J Clin Microbiol. 2016 Oct;54(10):2498-502. doi: 10.1128/JCM.01196-16. Epub 2016 Jul 20.

19.

Identification of a Transcription Factor That Regulates Host Cell Exit and Virulence of Mycobacterium tuberculosis.

Srinivasan L, Gurses SA, Hurley BE, Miller JL, Karakousis PC, Briken V.

PLoS Pathog. 2016 May 18;12(5):e1005652. doi: 10.1371/journal.ppat.1005652. eCollection 2016 May.

20.

Statin adjunctive therapy shortens the duration of TB treatment in mice.

Dutta NK, Bruiners N, Pinn ML, Zimmerman MD, Prideaux B, Dartois V, Gennaro ML, Karakousis PC.

J Antimicrob Chemother. 2016 Jun;71(6):1570-7. doi: 10.1093/jac/dkw014. Epub 2016 Feb 21.

21.

TLR2-Modulating Lipoproteins of the Mycobacterium tuberculosis Complex Enhance the HIV Infectivity of CD4+ T Cells.

Skerry C, Klinkenberg LG, Page KR, Karakousis PC.

PLoS One. 2016 Jan 25;11(1):e0147192. doi: 10.1371/journal.pone.0147192. eCollection 2016.

22.

Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin?

Dutta NK, Karakousis PC.

Front Microbiol. 2015 Oct 14;6:1117. doi: 10.3389/fmicb.2015.01117. eCollection 2015. No abstract available.

23.

A tuberculosis ontology for host systems biology.

Levine DM, Dutta NK, Eckels J, Scanga C, Stein C, Mehra S, Kaushal D, Karakousis PC, Salamon H.

Tuberculosis (Edinb). 2015 Sep;95(5):570-4. doi: 10.1016/j.tube.2015.05.012. Epub 2015 Jun 30.

24.

Lesion-Specific Immune Response in Granulomas of Patients with Pulmonary Tuberculosis: A Pilot Study.

Subbian S, Tsenova L, Kim MJ, Wainwright HC, Visser A, Bandyopadhyay N, Bader JS, Karakousis PC, Murrmann GB, Bekker LG, Russell DG, Kaplan G.

PLoS One. 2015 Jul 2;10(7):e0132249. doi: 10.1371/journal.pone.0132249. eCollection 2015.

25.

Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives.

Via LE, Savic R, Weiner DM, Zimmerman MD, Prideaux B, Irwin SM, Lyon E, O'Brien P, Gopal P, Eum S, Lee M, Lanoix JP, Dutta NK, Shim T, Cho JS, Kim W, Karakousis PC, Lenaerts A, Nuermberger E, Barry CE 3rd, Dartois V.

ACS Infect Dis. 2015 May 8;1(5):203-214.

26.

Differential expression of miRNAs and their relation to active tuberculosis.

Xu Z, Zhou A, Ni J, Zhang Q, Wang Y, Lu J, Wu W, Karakousis PC, Lu S, Yao Y.

Tuberculosis (Edinb). 2015 Jul;95(4):395-403. doi: 10.1016/j.tube.2015.02.043. Epub 2015 Mar 6.

PMID:
25936536
27.

Deficiency of the novel exopolyphosphatase Rv1026/PPX2 leads to metabolic downshift and altered cell wall permeability in Mycobacterium tuberculosis.

Chuang YM, Bandyopadhyay N, Rifat D, Rubin H, Bader JS, Karakousis PC.

MBio. 2015 Mar 17;6(2):e02428. doi: 10.1128/mBio.02428-14.

28.

Metabolomics specificity of tuberculosis plasma revealed by (1)H NMR spectroscopy.

Zhou A, Ni J, Xu Z, Wang Y, Zhang H, Wu W, Lu S, Karakousis PC, Yao YF.

Tuberculosis (Edinb). 2015 May;95(3):294-302. doi: 10.1016/j.tube.2015.02.038. Epub 2015 Feb 14.

29.

Future target-based drug discovery for tuberculosis?

Kana BD, Karakousis PC, Parish T, Dick T.

Tuberculosis (Edinb). 2014 Dec;94(6):551-6. Review.

30.

senX3-independent contribution of regX3 to Mycobacterium tuberculosis virulence.

Rifat D, Belchis DA, Karakousis PC.

BMC Microbiol. 2014 Oct 25;14:265. doi: 10.1186/s12866-014-0265-8.

31.

Thioridazine for treatment of tuberculosis: promises and pitfalls.

Dutta NK, Karakousis PC.

Tuberculosis (Edinb). 2014 Dec;94(6):708-11. doi: 10.1016/j.tube.2014.09.001. Epub 2014 Sep 19.

PMID:
25293998
32.

PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice.

Dutta NK, Karakousis PC.

Int J Antimicrob Agents. 2014 Dec;44(6):564-6. doi: 10.1016/j.ijantimicag.2014.07.012. Epub 2014 Sep 16.

33.

Latent tuberculosis infection: myths, models, and molecular mechanisms.

Dutta NK, Karakousis PC.

Microbiol Mol Biol Rev. 2014 Sep;78(3):343-71. doi: 10.1128/MMBR.00010-14. Review.

34.

Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.

Dutta NK, Pinn ML, Karakousis PC.

Antimicrob Agents Chemother. 2014 Sep;58(9):5567-9. doi: 10.1128/AAC.03408-14. Epub 2014 Jun 16.

35.

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

Skerry C, Pinn ML, Bruiners N, Pine R, Gennaro ML, Karakousis PC.

J Antimicrob Chemother. 2014 Sep;69(9):2453-7. doi: 10.1093/jac/dku166. Epub 2014 May 22.

36.

Deficiency of double-strand DNA break repair does not impair Mycobacterium tuberculosis virulence in multiple animal models of infection.

Heaton BE, Barkan D, Bongiorno P, Karakousis PC, Glickman MS.

Infect Immun. 2014 Aug;82(8):3177-85. doi: 10.1128/IAI.01540-14. Epub 2014 May 19.

37.

Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice.

Dutta NK, Illei PB, Jain SK, Karakousis PC.

Am J Pathol. 2014 Jul;184(7):2045-55. doi: 10.1016/j.ajpath.2014.03.008. Epub 2014 May 9.

38.

Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis.

Dutta NK, Pinn ML, Karakousis PC.

Antimicrob Agents Chemother. 2014 Jul;58(7):4048-53. doi: 10.1128/AAC.02981-14. Epub 2014 May 5.

39.

Replication of Mycobacterium tuberculosis in retinal pigment epithelium.

Nazari H, Karakousis PC, Rao NA.

JAMA Ophthalmol. 2014 Jun;132(6):724-9. doi: 10.1001/jamaophthalmol.2014.270.

PMID:
24723139
40.

Differential regulation of the two-component regulatory system senX3-regX3 in Mycobacterium tuberculosis.

Rifat D, Karakousis PC.

Microbiology. 2014 Jun;160(Pt 6):1125-33. doi: 10.1099/mic.0.077180-0. Epub 2014 Apr 10.

41.

Systems biology-based identification of Mycobacterium tuberculosis persistence genes in mouse lungs.

Dutta NK, Bandyopadhyay N, Veeramani B, Lamichhane G, Karakousis PC, Bader JS.

MBio. 2014 Feb 18;5(1). pii: e01066-13. doi: 10.1128/mBio.01066-13.

42.

Application of (1)h NMR spectroscopy-based metabolomics to sera of tuberculosis patients.

Zhou A, Ni J, Xu Z, Wang Y, Lu S, Sha W, Karakousis PC, Yao YF.

J Proteome Res. 2013 Oct 4;12(10):4642-9. doi: 10.1021/pr4007359. Epub 2013 Sep 10.

43.

Early innate immunity determines outcome of Mycobacterium tuberculosis pulmonary infection in rabbits.

Subbian S, Bandyopadhyay N, Tsenova L, O'Brien P, Khetani V, Kushner NL, Peixoto B, Soteropoulos P, Bader JS, Karakousis PC, Fallows D, Kaplan G.

Cell Commun Signal. 2013 Aug 19;11:60. doi: 10.1186/1478-811X-11-60.

44.
45.

Vaccination with recombinant Mycobacterium tuberculosis PknD attenuates bacterial dissemination to the brain in guinea pigs.

Skerry C, Pokkali S, Pinn M, Be NA, Harper J, Karakousis PC, Jain SK.

PLoS One. 2013 Jun 11;8(6):e66310. doi: 10.1371/journal.pone.0066310. Print 2013.

46.

Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.

Dutta NK, Alsultan A, Gniadek TJ, Belchis DA, Pinn ML, Mdluli KE, Nuermberger EL, Peloquin CA, Karakousis PC.

Antimicrob Agents Chemother. 2013 Aug;57(8):3910-6. doi: 10.1128/AAC.00761-13. Epub 2013 Jun 3.

47.

The polyphosphate kinase gene ppk2 is required for Mycobacterium tuberculosis inorganic polyphosphate regulation and virulence.

Chuang YM, Belchis DA, Karakousis PC.

MBio. 2013 May 21;4(3):e00039-13. doi: 10.1128/mBio.00039-13.

48.

Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis.

Dutta NK, Pinn ML, Zhao M, Rudek MA, Karakousis PC.

J Antimicrob Chemother. 2013 Jun;68(6):1327-30. doi: 10.1093/jac/dkt037. Epub 2013 Mar 5.

49.

Molecular immunologic correlates of spontaneous latency in a rabbit model of pulmonary tuberculosis.

Subbian S, O'Brien P, Kushner NL, Yang G, Tsenova L, Peixoto B, Bandyopadhyay N, Bader JS, Karakousis PC, Fallows D, Kaplan G.

Cell Commun Signal. 2013 Feb 28;11(1):16. doi: 10.1186/1478-811X-11-16.

50.

Rv1894c is a novel hypoxia-induced nitronate monooxygenase required for Mycobacterium tuberculosis virulence.

Klinkenberg LG, Karakousis PC.

J Infect Dis. 2013 May 15;207(10):1525-34. doi: 10.1093/infdis/jit049. Epub 2013 Feb 13.

Supplemental Content

Loading ...
Support Center